MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: First biomarker for prostate cancer outcome

Back to prostate cancer blog Blogs list Cancer blog  


Subscribe To Prostate Cancer Blog RSS Feed  RSS content feed What is RSS feed?

First biomarker for prostate cancer outcome




Mayo Clinic scientists have identified the first immune molecule that appears to play a role in prostate cancer development and in predicting cancer recurrence and progression after surgery. The report on the B7-H3 molecule by Mayo Clinic Cancer Center appears today in Cancer Research.

This discovery will allow physicians to individualize therapy and observation plans for patients with prostate cancer, says Timothy Roth, M.D., a Mayo Clinic urology resident and lead author of the study. Being able to tell a patient his specific risk after surgery, and perhaps even previous to surgery, will be a huge step forward.



First biomarker for prostate cancer outcome

Until now there were no strongly-predictive molecules for prostate cancer. The most notable other prostate biomarkers, prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA) are useful to diagnose prostate cancer. However, PSA tends to leave prostate cancer cells and migrate throughout the body, making it a poor target for treatment.


Todays Research

In this study, Mayo scientists demonstrate that nearly all normal, pre-cancerous and malignant prostate cells have B7-H3 on their surface. Unlike PSA, B7-H3 stays attached to the surface of prostate cancer cells and does not appear to migrate, thus making B7-H3 a especially attractive target for treatment. The scientists think that B7-H3 kills or paralyzes immune cells that are trying to attack the cancer. Their findings indicate that B7-H3 may prove useful as a diagnostic, prognostic and even therapeutic tool because it is stably or increasingly displayed by tumor cells as prostate cancers develop -- even after initiation of anti-hormone treatment, which is the most common therapy for advanced prostate cancer.

The physician-research team examined tissue from 338 consecutive patients who had cancers confined to the prostate and were treated exclusively with a radical prostatectomy (surgery to remove the prostate) between 1995 and 1998. All tumors and premalignant tissues displayed B7-H3, but patients with the highest levels of B7-H3 within their prostate tumors (19.8 percent) were four times more likely to experience cancer progression in comparison to those with weak levels of B7-H3 within their tumors. Moderate levels of B7-H3 also correlated with a slightly higher risk of recurrence (35 percent).

Because B7-H3 is present in all prostate cancer tumors, and marked levels predict recurrence, we are able to forecast with much greater certainty the likelihood of cancer progression, regardless of therapeutic intervention, says Eugene Kwon, M.D., a senior investigator and urologist at Mayo Clinic.

For some patients, a watchful waiting clinical approach is sometimes used to manage prostate cancer previous to resorting to treatment to see if the cancer becomes increasingly aggressive. The scientists say that the evaluation of B7-H3 levels in prostate biopsies from patients may soon help to determine which patients may benefit from a watchful waiting strategy versus early aggressive therapy.


Individualized Medicine Emerges

Mayo Clinics findings on biomarker identification may accelerate the development of new forms of treatment, say the researchers. Additionally, prostate cancer now joins kidney cancer as a malignancy that can be tracked and predicted based on the presence of B7-H immune molecules.

This is the way of the future, says Dr. Kwon, We are becoming educated about ways to flesh out the molecular signatures of each patients cancer. Using such molecular signatures will facilitate, for the first time, a truly individualized approach to prescribing the most appropriate treatment for a given patient. We will soon be able to tailor-make therapies for each persons cancer.


B7-H3 in the Future

To understand how B7-H3 affects the immune system, and whether a mutation of B7-H3 is involved in the anti-immune activity, more research is necessary. Mayo is planning clinical trials for many cancers in late 2008, and scientists are currently developing the necessary therapeutic antibodies to be used in these studies. Investigators expect that clinical laboratory tests for the B7-H proteins may become available at Mayo to assist with the assessment of patients with kidney cancer by late 2007 or early 2008, and then for patients with prostate cancer shortly thereafter.


Unique Mayo Registry Key

This study was possible because of Mayos unique patient registry for prostate cancer. The registry contains hundreds of discrete pieces of information, ranging from environmental factors to specific medical test results, for more than 15,000 patients with prostate cancer, all followed prospectively since the first patient was entered into the database in 1970. The Mayo Clinic prostate cancer and kidney cancer registries represent the most detailed and complete cancer reference tools in the world. Using the latter registry, Mayo researchers were previously able to link high levels of another B7-H molecule, B7-H1, to poor kidney cancer outcomes, including significantly shortened survival times.

Without the key road maps provided by these registries, the recognition of important molecules that drive cancer would not be feasible, say the researchers. Use of these patient registries enables laboratory science to be directly associated with patient care and survival following therapy.

To a large extent, working with these registries dramatically lessens the time, resources and effort that are mandatory to link a candidate molecule to its role in cancer development and progression, says Dr. Kwon, who is also the co-director of the Cancer Immunology and Immunotherapy Program in Mayo Clinic Cancer Center. Our studies are the very first to provide a clear link between immune molecules and the behaviors of various cancers.

Dr. Kwon and his fellow scientists have been charged by Mayo Clinic to investigate all cancers for immune molecules that may govern cancer behavior while doubling as new therapeutic targets -- identifying future research targets.


Background: B7-H3 and Immunology Research at Mayo

Mayo Clinic Cancer Center was the first to discover the B7-H family of immune molecules -- proteins that normally help regulate the immune response process. Mayo researchers showed that B7-H3 and other members of the B7-H family, such as B7-H1, can have an inhibitory function and actually protect cancers as they develop.

Mayo Clinic identified B7-H3 as a new molecule in 2001. Mayo scientists published the first research identifying an immune molecules role in cancer, with multiple publications pertaining to the role of B7-H1 in heralding a poor prognosis for patients with kidney cancer. Eventhough many hypotheses predicted that these molecules might enable cancer development, no one had shown it clinically previous to these studies.

Thus far, the researchers have spent significant time researching the B7-H family of molecules. They have evaluated tens of thousands of samples from at least 30 different cancers, including cancers of the breast, colon, pancreas, brain and ovary, as well as mesothelioma.


Posted by: Mark    Source




Did you know?
Mayo Clinic scientists have identified the first immune molecule that appears to play a role in prostate cancer development and in predicting cancer recurrence and progression after surgery. The report on the B7-H3 molecule by Mayo Clinic Cancer Center appears today in Cancer Research.

Medicineworld.org: First biomarker for prostate cancer outcome

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.